InvestorLens

HAE — HAEMONETICS CORP MASS

Health Care

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying HAE?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 2 buying vs 0 selling last quarter
65
Macro Tailwind
Macro conditions are mixed for this sector
53
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their HAE position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Howard Marks, Ray Dalio)
  • +5 tracked investors reported holding HAE at their latest filing
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About HAEMONETICS CORP MASS (HAE)

HAEMONETICS CORP MASS (HAE) appears in the most recent 13F filings of 5 tracked institutional investors. HAEMONETICS CORP MASS is classified in the Health Care sector. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $116M. Across recent filings, tracked investors recorded 7 new positions, 10 increased, 10 reduced, and 5 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in HAE

53
/100
Mixed Activity
Added / Increased17
Reduced10
Exited5
BearishBullish
Crowded Trade Score™

How many top investors track HAE

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

HAE Ownership Composition

How HAEMONETICS CORP MASS is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
96% of tracked value
Institutions
5
tracked investors
Total Reported
$180.6M
combined 13F value
Types3
  • Multi-Strategy / Quant96.3%
  • Macro2.5%
  • Value & Distressed1.2%
Multi-Strategy / Quant(3)
96.3%
Macro(1)
2.5%
Value & Distressed(1)
1.2%

Tracked investors currently reporting HAE

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    1.5M
    Value
    $115.5M
    % Portfolio
    0.01%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    109.2K
    Value
    $8.2M
    % Portfolio
    0.01%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    670.4K
    Value
    $50.3M
    % Portfolio
    0.02%
  • Howard MarksJun 30, 2026
    Oaktree Capital Management
    Shares
    2.1M
    Value
    $2.1M
    % Portfolio
    0.03%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    59.7K
    Value
    $4.5M
    % Portfolio
    0.02%

Previously held HAE

These investors reported HAE in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Paul Tudor JonesTudor Investment Corp56.3K$4.5MDec 31, 2025

Recent activity

Frequently asked questions

How many institutional investors hold HAE?
5 tracked institutional investors disclosed a position in HAE (HAEMONETICS CORP MASS) in their most recent 13F filing.
Who is the largest institutional holder of HAE?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in HAE, valued at $116M.
Did institutional ownership of HAE increase or decrease?
Across recent 13F filings, tracked investors recorded 7 new positions, 10 increased, 10 reduced, and 5 fully exited HAE.
What sector is HAE in?
HAEMONETICS CORP MASS is classified in the Health Care GICS sector.
Where does this HAE ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.